Wheatland Advisors Inc. lessened its stake in Eli Lilly and Company (NYSE:LLY) by 4.6% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 29,228 shares of the company’s stock after selling 1,397 shares during the quarter. Eli Lilly and comprises about 2.2% of Wheatland Advisors Inc.’s investment portfolio, making the stock its 14th largest holding. Wheatland Advisors Inc.’s holdings in Eli Lilly and were worth $2,405,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Joel Isaacson & Co. LLC increased its holdings in Eli Lilly and by 1.5% in the first quarter. Joel Isaacson & Co. LLC now owns 3,364 shares of the company’s stock valued at $283,000 after purchasing an additional 50 shares during the last quarter. Sumitomo Life Insurance Co. increased its holdings in Eli Lilly and by 4.4% in the second quarter. Sumitomo Life Insurance Co. now owns 32,507 shares of the company’s stock valued at $2,675,000 after purchasing an additional 1,370 shares during the last quarter. Russell Investments Group Ltd. increased its holdings in Eli Lilly and by 7.8% in the second quarter. Russell Investments Group Ltd. now owns 671,327 shares of the company’s stock valued at $55,258,000 after purchasing an additional 48,706 shares during the last quarter. Renaissance Technologies LLC increased its holdings in Eli Lilly and by 93.6% in the first quarter. Renaissance Technologies LLC now owns 2,980,400 shares of the company’s stock valued at $250,681,000 after purchasing an additional 1,441,200 shares during the last quarter. Finally, Stephens Inc. AR increased its holdings in Eli Lilly and by 4.5% in the first quarter. Stephens Inc. AR now owns 44,023 shares of the company’s stock valued at $3,703,000 after purchasing an additional 1,901 shares during the last quarter. Institutional investors and hedge funds own 75.72% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Eli Lilly and Company (LLY) Position Reduced by Wheatland Advisors Inc.” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this news story can be accessed at https://www.thecerbatgem.com/2017/10/05/eli-lilly-and-company-lly-position-reduced-by-wheatland-advisors-inc.html.

In related news, major shareholder Lilly Endowment Inc sold 220,000 shares of the business’s stock in a transaction dated Monday, July 31st. The stock was sold at an average price of $83.09, for a total value of $18,279,800.00. Following the completion of the sale, the insider now directly owns 124,049,283 shares of the company’s stock, valued at approximately $10,307,254,924.47. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders sold a total of 785,000 shares of company stock valued at $65,153,600 over the last ninety days. 0.20% of the stock is currently owned by corporate insiders.

A number of equities research analysts recently commented on the company. Cowen and Company reiterated a “buy” rating and issued a $95.00 price objective on shares of Eli Lilly and in a report on Wednesday. BMO Capital Markets reiterated a “sell” rating and issued a $71.00 price objective on shares of Eli Lilly and in a report on Thursday, September 28th. Morgan Stanley reiterated a “hold” rating and issued a $86.00 price objective on shares of Eli Lilly and in a report on Friday, September 15th. Jefferies Group LLC reiterated a “buy” rating and issued a $89.00 price objective on shares of Eli Lilly and in a report on Monday, September 11th. Finally, Piper Jaffray Companies reiterated an “overweight” rating and issued a $105.00 price objective (up previously from $103.00) on shares of Eli Lilly and in a report on Friday, September 8th. Three investment analysts have rated the stock with a sell rating, seven have issued a hold rating and twelve have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $88.27.

Eli Lilly and Company (LLY) opened at 86.96 on Thursday. Eli Lilly and Company has a 52-week low of $64.18 and a 52-week high of $87.16. The stock’s 50 day moving average price is $81.75 and its 200 day moving average price is $82.08. The firm has a market capitalization of $91.74 billion, a PE ratio of 37.63 and a beta of 0.34.

Eli Lilly and (NYSE:LLY) last issued its earnings results on Tuesday, July 25th. The company reported $1.11 EPS for the quarter, beating analysts’ consensus estimates of $1.05 by $0.06. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The business had revenue of $5.82 billion during the quarter, compared to analyst estimates of $5.60 billion. During the same period in the previous year, the company posted $0.86 EPS. The firm’s revenue was up 7.8% compared to the same quarter last year. On average, analysts predict that Eli Lilly and Company will post $4.16 EPS for the current fiscal year.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Stock Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related stocks with our FREE daily email newsletter.